Rare Dermatology News

Spotlight On

Cutaneous melanoma

Melanoma is a malignancy of pigment-producing cells (melanocytes) located predominantly in the skin, but also found in the eyes, ears, GI tract, leptomeninges, and oral and genital mucous membranes

Prevelance

Unknown

US Estimated

Unknown

Europe Estimated

Age of Onset

ageofonset-adult.svg

ICD-10

C43

Inheritance

Autosomal dominant

autosomaldominant.svg

5% to 10% of all melanomas arise in multiple-case families and may be inherited in an autosomal dominant fashion

Autosomal recessive

no.svg

Mitochondrial/Multigenic

no.svg

X-linked dominant

no.svg

X-linked recessive

no.svg

Rare View

Malignant melanoma is the most lethal form of skin cancer. In the last 50 years its incidence has risen faster than almost any other cancer. Melanoma represents less than 5% of all cutaneous malignancies, but the vast majority of skin cancer deaths. The worldwide incidence of melanoma has risen rapidly over the course of the last 50 years. Its incidence is greatest among fair-skinned populations, and in regions of lower latitude.

rv-melanoma.svg

5 Facts you should know

FACT

1

Cutaneous melanoma is responsible for the vast majority of skin cancer-related deaths in the United States

FACT

2

The worldwide incidence of cutaneous melanoma has been increasing annually at a more rapid rate compared to any other type of cancer

FACT

3

Known risk factors include genetic defects, environmental exposures, and a combination of both

FACT

4

Inherited phenotypic traits associated with melanoma include fair skin, light hair, red hair, freckles, and light eye color

FACT

5

Excisional biopsy of the entire specimen with narrow margins is the most effective way to facilitate proper diagnosis and treatment planning

Cutaneous melanoma is also know as...

Cutaneous melanoma

Melanoma skin cancer, skin cancer

What’s your Rare IQ?

Based on recent data, what percentage of high-risk primary melanomas recur within two years of diagnosis?

Top Clinical Trials

TitleDescriptionPhasesStatusInterventionsMore Information
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)Phase 3, multicenter, international, open-label, randomized, 2-arm trial investigating the safety and efficacy of IO102-IO103 in combination with pembrolizumab as first-line treatment for patients with previously untreated unresectable or metastatic (advanced) melanoma.Phase 3RecruitingDrug: IO102-IO103|Drug: PembrolizumabClick here for more information
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C Melanoma PatientsThe trial aims to evaluate the efficacy of Daromun neoadjuvant treatment followed by surgery and adjuvant therapy to improve in a statistically significant manner the recurrence-free survival (RFS) of Stage IIIB/C melanoma patients with respect to the standard of care (surgery and adjuvant therapy).Phase 3RecruitingDrug: Daromun|Procedure: Surgery|Drug: Adjuvant therapyClick here for more information
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic MelanomaThe purpose of this study is to learn about the effects of three study medicines (encorafenib, binimetinib, and pembrolizumab) given together for the treatment of melanoma.Phase 3RecruitingDrug: Encorafenib|Drug: Binimetinib|Drug: PembrolizumabClick here for more information
Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for RecurrenceThe main purpose of this study is to compare the efficacy of bempegaldesleukin plus nivolumab versus nivolumab in patients with completely resected Stage IIIA/B/C/D, or Stage IV cutaneous melanoma who are at high risk for recurrence.Phase 3RecruitingBiological: Bempegaldesleukin|Biological: NivolumabClick here for more information
CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced MelanomaCMP-001-011 is a Phase 2/3 study of CMP-001 intratumoral (IT) and nivolumab intravenous (IV) compared to nivolumab monotherapy administered to participants with unresectable or metastatic melanoma.Phase 2|Phase 3RecruitingDrug: CMP-001|Drug: NivolumabClick here for more information
Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III MelanomaThis phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgeryPhase 3RecruitingDrug: Neoadjuvant ipilimumab + nivolumab|Drug: Adjuvant nivolumabClick here for more information
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced MelanomaThis phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery.Phase 2|Phase 3RecruitingBiological: Ipilimumab|Biological: Nivolumab|Biological: SargramostimClick here for more information
Evaluation of the Length of Treatment With PD-1/PD-L1 Inhibitors in Patients With Advanced Solid TumorsThe investigators are proposing a trial that will randomize patients who have disease stability to stop treatment at 1 year or continue treatment until disease progression. The investigators anticipate that the results of this study will answer questions regarding the optimal duration of treatment. therapy.Phase 3RecruitingDrug: Continue PD-1/PD-L1 Inhibitors treatment|Other: Discontinue PD-1/PD-L1-1 inhibitorClick here for more information

Top Treatments in Research

AgentClass/Mechanism of ActionDevelopment StatusCompanyClinical StudiesMore Information
IO102-IO103/PembrolizumabIO102-IO103 is an investigational cancer vaccine designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as Indoleamine 2,3-dehydrogenase (IDO) and PD-L1.Pembrolizumab (Keytruda) is a humanized monoclonal antibody to programmed cell death receptor 1 (PD-1), which results in an increased immune reactivity that can break tolerance and is used in the immunotherapy of cancer.Phase 3IO BiotechClick here for more informationClick here for more information
DaromunDaromun (Philogen) is a combination of Darleukin, a human vascular targeting monoclonal antibody (L19) fused to interleukin-2 (IL-2), and Fibromun, the L19 antibody linked to tumor necrosis factor (TNF). Phase 3PhilogenClick here for more informationClick here for more information
Encorafenib/Binimetinib/PembrolizumabEncorafenib is a small molecule BRAF inhibitor that targets key enzymes in the MAPK signaling pathway. Binimetinib is an uncompetitive, small molecule inhibitor of selective mitogen-activated protein kinase (MEK1/2). .Pembrolizumab (Keytruda) is a humanized monoclonal antibody to programmed cell death receptor 1 (PD-1), which results in an increased immune reactivity that can break tolerance and is used in the immunotherapy of cancer.Phase 3PfizerClick here for more informationClick here for more information
Bempegaldesleukin/NivolumabBempegaldesleukin is a PEGylated interleukin-2 (IL-2) acting as a CD122-preferential IL-2 pathway agonist designed to activate and proliferate CD8 + T cells and NK cells. Nivolumab is a human recombinant monoclonal immunoglobulin G4 antibody to the programmed cell death receptor-1 (PD-1) which has distinctive immunomodulatory activity and is used in cancer immunotherapy.Phase 3Nektar TherapeuticsClick here for more informationClick here for more information
CMP-001/NivolumabAnti-Qβ-coated CMP-001 induces IFN-α production by pDCs which has secondary effects on a variety of cells including monocytes. Nivolumab is a human recombinant monoclonal immunoglobulin G4 antibody to the programmed cell death receptor-1 (PD-1) which has distinctive immunomodulatory activity and is used in cancer immunotherapy.Phase 2|Phase 3Checkmate PharmaceuticalsClick here for more informationClick here for more information
Neoadjuvant ipilimumab + nivolumab/Adjuvant nivolumabIpilimumab, is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4. Nivolumab is a human recombinant monoclonal immunoglobulin G4 antibody to the programmed cell death receptor-1 (PD-1) which has distinctive immunomodulatory activity and is used in cancer immunotherapy. Phase 3The Netherlands Cancer InstituteClick here for more informationClick here for more information
Ipilimumab/Nivolumab/SargramostimIpilimumab, is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4. Nivolumab is a human recombinant monoclonal immunoglobulin G4 antibody to the programmed cell death receptor-1 (PD-1) which has distinctive immunomodulatory activity and is used in cancer immunotherapy. Phase 2|Phase 3National Cancer Institute (NCI)Click here for more informationClick here for more information
Continue PD-1/PD-L1 Inhibitors treatment/Discontinue PD-1/PD-L1-1 inhibitorPD-1 inhibitors and PD-L1 inhibitors are a group of checkpoint inhibitor anticancer drugs that block the activity of PD-1 and PDL1 immune checkpoint proteins present on the surface of cells.
Phase 3Antoinette J Wozniak, University of PittsburghClick here for more informationClick here for more information

Medline Plus, National Library of Medicine